High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms

Modern Pathology

Volumn 27, Issue 11, 2014, Pages 1447-1454

  Pozdnyakova, Olga ^a   Wu, Kaida ^b   Patki, Abhay ^b,e   Rodig, Scott J ^a   Thiele, Juergen ^c   Hasserjian, Robert P ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Sanofi Oncology   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Blueprint Medicines   (United States)

Author keywords

anti JAK2 therapy; bone marrow; collagen deposition; hematopoietic cellularity; inter rater agreement; reticulin fibrosis

Indexed keywords

CYTOTOXIC AGENT; FEDRATINIB; HYDROXYUREA; ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PROTEIN KINASE INHIBITOR; PYRROLIDINE DERIVATIVE; RETICULIN; SULFONAMIDE;

ARTICLE; BONE MARROW BIOPSY; CANCER GRADING; CANCER THERAPY; CELLULAR PARAMETERS; DISEASE CLASSIFICATION; HEMATOPATHOLOGIST; HEMATOPOIETIC CELLULARITY; HUMAN; MAJOR CLINICAL STUDY; MYELOPROLIFERATIVE NEOPLASM; PATHOLOGIST; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REPRODUCIBILITY; RETICULIN FIBROSIS GRADING SYSTEM; STAINING; WORLD HEALTH ORGANIZATION; ANTAGONISTS AND INHIBITORS; BIOPSY; BONE MARROW; BONE MARROW EXAMINATION; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; METABOLISM; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDERS; OBSERVER VARIATION; PATHOLOGY; POLYCYTHEMIA VERA; PREDICTIVE VALUE; THROMBOCYTHEMIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOPSY; BONE MARROW; BONE MARROW EXAMINATION; FIBROSIS; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; NEOPLASM GRADING; OBSERVER VARIATION; POLYCYTHEMIA VERA; PREDICTIVE VALUE OF TESTS; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRROLIDINES; REPRODUCIBILITY OF RESULTS; RETICULIN; SULFONAMIDES; THROMBOCYTHEMIA, ESSENTIAL; TREATMENT OUTCOME;

EID: 84926143782     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.69     Document Type: Article

References (51)

1. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
2. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
3. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-2390.
4. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with non-mutated JAK2. N Engl J Med 2013;369:2391-2405.
5. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; PMID: 24402162 (e-pub ahead of print).
6. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol 2002;70:283-291.
7. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients. Leuk Lymphoma 2003;44:949-953.
8. Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 2012;7:e35631.
9. Buhr T, Busche G, Choritz H, et al. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 2003;119:152-158.
10. Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood 2012;119: 2239-2241.
11. Ellis JT, Peterson P, Geller SA, et al. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 1986;23:144-155.
12. Mesa RA, Green A, Barosi G, et al. MPN-associated myelofibrosis (MPN-MF). Leuk Res 2011;35:12-13.
13. Kuter DJ, Bain B, Mufti G, et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007;139: 351-362.
14. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90: 1128-1132.
15. Thiele J, Kvasnicka HM, Tefferi A, et al. Primary myelofibrosis. In: Swerdlow SH, Campo E, Harris NL, et al (eds). WHO Classifications of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press: Lyon, France; 2008, pp 44-47.
16. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115: 1703-1708.
17. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392-397.
18. Kvasnicka HM, Thiele J. The impact of clinicopatho-logical studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost 2006;32:362-371.
19. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 2006;85: 226-232.
20. Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelo-fibrosis. Blood 2008;111:1862-1865.
21. Gianelli U, Vener C, Bossi A, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol 2012;25:1193-1202.
22. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008;22:437-438.
23. Sale GE, Deeg HJ, Porter BA. Regression of myelo-fibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biol Blood Marrow Transplant 2006;12:1285-1294.
24. Thiele J, Kvasnicka HM, Dietrich H, et al. Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation. Histol Histopathol 2005;20: 879-889.
25. Kroger N, Kvasnicka M, Thiele J. Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis. Fibrogenesis Tissue Repair 2012;5(Suppl 1):S25.
26. Hasserjian RP, Boecklin F, Parker S, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am. J Clin Pathol 2002;117: 360-367.
27. Pullarkat V, Bass RD, Gong JZ, et al. Primary autoimmune myelofibrosis: definition of a distinct clinico-pathologic syndrome. Am J Hematol 2003;72:8-12.
28. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients. Histopathology 2005;46:540-550.
29. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012;120:1202-1209.
30. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibro-sis. N Engl J Med 2012;366:799-807.
31. Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelo-fibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014;123:1833-1835.
32. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelo-fibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013;98:1865-1871.
33. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-798.
34. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-4053.
35. Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2013;31:1285-1292.
36. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis. Histo-pathology 2003;43:470-479.
37. Thiele J, Kvasnicka HM, Schmitt-Graff A, et al. Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis. Histol Histopathol 2004;19:239-250.
38. Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 2013;98:1872-1876.
39. Kvasnicka H-M, Thiele J, Bueso-Ramos CE, et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelo-fibrosis. ASCO Meeting Abstracts 2013;31:7030.
40. Jamieson C, Hasserjian RP, Gotlib J, et al. Effect of treatment with the JAK2-selective inhibitor fedratinib (SAR302503) on bone marrow histology in patients with myeloproliferative neoplasms with myelofibrosis. Blood 2013;122:2823.
41. Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential throm-bocythemia and myelofibrosis. Expert Rev Hematol 2013;6:49-58.
42. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombo-cythemia: an ELN and IWG-MRT consensus project. Blood 2013;121:4778-4781.
43. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013;122:1395-1398.
44. Thiele J, Kvasnicka HM. Myelofibrosis-what's in a name? Consensus on definition and EUMNET grading. Pathobiology 2007;74:89-96.
45. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008;111:60-70.
46. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009;27:2991-2999.
47. Teman CJ, Wilson AR, Perkins SL, et al. Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: a computer-assisted image study. Leuk Res 2010;34:871-876.
48. Barbui T, Thiele J, Vannucchi AM, et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013;27:1953-1958.
49. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33: 159-174.
50. Madelung AB, Bondo H, Stamp I, et al. World Health Organization-defined classification of myelo-proliferative neoplasms: morphological reproduci-bility and clinical correlations-the Danish experience. Am J Hematol 2013;88:1012-1016.
51. Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013;122:4055.